Derivation and validation of an accurate estimation of CD4 counts from the absolute lymphocyte count in virologically suppressed and immunologically reconstituted HIV infected adults.
BACKGROUND
A simple method to estimate CD4 counts in stable, HIV infected virologically-suppressed and immune-reconstituted adults could save the expense of unnecessary formal testing.


METHODS
Using a baseline CD4 percent, CD4 counts were estimated from subsequent absolute lymphocyte counts (ALC) measured by an automated FBC machine (CD4 estimate calculated by the ALC multiplied by the baseline CD4 percent). The accuracy of this approach was established in a large, retrospective clinical laboratory dataset of virologically-suppressed HIV infected subjects. A case-control study explored important clinical factors for accurate estimates, and a heuristic algorithm was derived and validated in a random sample.


RESULTS
Data from 3,630 subjects were available. CD4 counts were generally accurately estimated, with a mean 6.1 % underestimation. Overall 83.3 % of CD4 estimates were within 25 % of the actual values, with 12.1 % CD4 counts underestimated by more than 25 %, and 4.5 % overestimated. The CD4 count was increasingly underestimated with time from baseline, and the degree of underestimation correlated with baseline CD4 percent (p < 0.0001). From the case-control study, baseline CD4 percent of ≥20, no illness requiring hospitalization and more than a year since starting or switch of anti-retroviral therapy were identified as significant predictors of inaccurate estimates. Employing this simple algorithm, CD4 estimate accuracy improved to a mean 1.3 % underestimation, and the proportion of estimates within 25 % of the actual value increased to 93.4 %.


CONCLUSIONS
In virologically-suppressed and immune-reconstituted HIV-infected adults, the CD4 count can be accurately estimated from the ALC using a baseline CD4 percent for at least 2 years after measurement.
Institute of Infectious Diseases and Epidemiology, , Tan Tock Seng Hospital, Singapore, Singapore. Barnaby_young@ttsh.com.sg.
Barnaby
B
Young
Institute of Infectious Diseases and Epidemiology, , Tan Tock Seng Hospital, Singapore, Singapore. Oon_tek_ng@ttsh.com.sg.|Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. Oon_tek_ng@ttsh.com.sg.
Oon Tek
OT
Ng
Institute of Infectious Diseases and Epidemiology, , Tan Tock Seng Hospital, Singapore, Singapore. David_lye@ttsh.com.sg.|Yong Yoo Lin School of Medicine, National University of Singapore, Singapore, Singapore. David_lye@ttsh.com.sg.
David Chien
DC
Lye
Institute of Infectious Diseases and Epidemiology, , Tan Tock Seng Hospital, Singapore, Singapore. Yee_sin_leo@ttsh.com.sg.|Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. Yee_sin_leo@ttsh.com.sg.
Yee Sin
YS
Leo
D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D016022:Case-Control Studies; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D012044:Regression Analysis; D015203:Reproducibility of Results; D012189:Retrospective Studies; D019562:Viral Load